Arca
Skip to content
Tools
Tools

NECTIN4: Nectin-4

Seems to be involved in cell adhesion through trans- homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on NECTIN4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate 1

Approved1

  • Enfortumab vedotin

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Enfortumab vedotinBoxed warningApprovedAstellas PharmaAntibody-drug conjugateBinding agentNectin-4 binding agent94

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerEnfortumab vedotinPhase 2RecruitingFox Chase Cancer CenterNov 2, 2026
        A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Enfortumab vedotinPhase 1 / Phase 2RecruitingDaiichi SankyoOct 22, 2026
        Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial CarcinomaEnfortumab vedotin—RecruitingComprehensive Cancer Center Munich (CCCM)Oct 13, 2026
        Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaEnfortumab vedotinPhase 2Not yet recruitingNorthwestern UniversityOct 7, 2026
        Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)Enfortumab vedotin—RecruitingLMU KlinikumOct 2, 2026
        Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerEnfortumab vedotinPhase 2Not yet recruitingFudan UniversitySep 17, 2026
        A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerEnfortumab vedotinPhase 2Not yet recruitingUniversity of UtahSep 16, 2026
        A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaEnfortumab vedotinPhase 2 / Phase 3RecruitingSummit TherapeuticsSep 11, 2026

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Ectodermal dysplasia-syndactyly syndrome
        0.78
        Urothelial carcinoma
        0.52
        Neoplasm
        0.40
        Urinary bladder carcinoma
        0.38
        Transitional cell carcinoma
        0.37
        Cancer
        0.35
        Urogenital neoplasm
        0.33
        Amelogenesis imperfecta
        0.18
        Hereditary disease
        0.16

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712928, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q96NY8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.